Alzheimer's disease: strategies for disease modification (Q37739810)

22 August 2017

1 reference

title

Alzheimer's disease: strategies for disease modification (English)

1 reference

22 August 2017

0 references

Martin Citron

1

1 reference

22 August 2017

1 May 2010

1 reference

Nature Reviews Drug Discovery

22 August 2017

1 reference

22 August 2017

9

1 reference

22 August 2017

387-398

1 reference

22 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2896

22 August 2017

0 references

cites work

NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies

1 reference

Molecular genetics of Alzheimer's disease

31 March 2020

1 reference

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

31 March 2020

1 reference

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

31 March 2020

1 reference

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

31 March 2020

1 reference

Tau suppression in a neurodegenerative mouse model improves memory function

31 March 2020

1 reference

Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics

31 March 2020

1 reference

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

31 March 2020

1 reference

A beta oligomers - a decade of discovery

31 March 2020

1 reference

Amyloid beta-peptide is produced by cultured cells during normal metabolism

31 March 2020

1 reference

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain

31 March 2020

1 reference

Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex

31 March 2020

1 reference

Presenilin diversifies its portfolio.

31 March 2020

1 reference

A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain

31 March 2020

1 reference

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation

31 March 2020

1 reference

Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation

31 March 2020

1 reference

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

31 March 2020

1 reference

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

31 March 2020

1 reference

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease

31 March 2020

1 reference

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

31 March 2020

1 reference

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

31 March 2020

1 reference

Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond.

31 March 2020

1 reference

Substrate-targeting gamma-secretase modulators

31 March 2020

1 reference

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

31 March 2020

1 reference

Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals

31 March 2020

1 reference

Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge

31 March 2020

1 reference

Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis.

31 March 2020

1 reference

Control of peripheral nerve myelination by the beta-secretase BACE1

31 March 2020

1 reference

Bace1 modulates myelination in the central and peripheral nervous system.

31 March 2020

1 reference

In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.

31 March 2020

1 reference

Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves

31 March 2020

1 reference

BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes

31 March 2020

1 reference

BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.

31 March 2020

1 reference

Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype?

31 March 2020

1 reference

Protease inhibitors: current status and future prospects

31 March 2020

1 reference

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

31 March 2020

1 reference

Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease

31 March 2020

1 reference

Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.

31 March 2020

1 reference

Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model.

31 March 2020

1 reference

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

31 March 2020

1 reference

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

31 March 2020

1 reference

RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier

31 March 2020

1 reference

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

31 March 2020

1 reference

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

31 March 2020

1 reference

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

31 March 2020

1 reference

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

31 March 2020

1 reference

Antibody-mediated resolution of light chain-associated amyloid deposits.

31 March 2020

1 reference

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

31 March 2020

1 reference

Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration

31 March 2020

1 reference

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

31 March 2020

1 reference

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

31 March 2020

1 reference

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

31 March 2020

1 reference

Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice

31 March 2020

1 reference

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

31 March 2020

1 reference

Active and passive immunotherapy for neurodegenerative disorders

31 March 2020

1 reference

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

31 March 2020

1 reference

Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis

31 March 2020

1 reference

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

31 March 2020

1 reference

Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease

31 March 2020

1 reference

Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease.

31 March 2020

1 reference

31 March 2020

1 reference

Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17

31 March 2020

1 reference

Tau protein, the paired helical filament and Alzheimer's disease

31 March 2020

2 references

31 March 2020

12 December 2020

Tau-based treatment strategies in neurodegenerative diseases

1 reference

Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now.

31 March 2020

1 reference

Development of tau aggregation inhibitors for Alzheimer's disease

31 March 2020

1 reference

O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks

31 March 2020

1 reference

Apolipoprotein E: cholesterol transport protein with expanding role in cell biology

31 March 2020

1 reference

Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses

31 March 2020

1 reference

Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy

31 March 2020

1 reference

Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease

31 March 2020

1 reference

Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease.

31 March 2020

1 reference

Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics

31 March 2020

1 reference

Association of metabolic syndrome with Alzheimer disease: a population-based study.

31 March 2020

1 reference

Cholesterol and the biology of Alzheimer's disease.

31 March 2020

1 reference

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

31 March 2020

1 reference

Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide

31 March 2020

1 reference

Therapeutic potential of statins in Alzheimer's disease.

31 March 2020

1 reference

The use of positron emission tomography in the clinical assessment of dementia

31 March 2020

1 reference

Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

31 March 2020

1 reference

Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.

31 March 2020

1 reference

Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications

31 March 2020

1 reference

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

31 March 2020

1 reference

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

31 March 2020

1 reference

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

31 March 2020

1 reference

2009 Alzheimer's disease facts and figures

31 March 2020

1 reference

Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed

31 March 2020

1 reference

Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease

31 March 2020

1 reference

Progress toward the discovery and development of efficacious BACE inhibitors

31 March 2020

1 reference

12 December 2020

Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention

1 reference

12 December 2020

The neurobiology of zinc in health and disease

1 reference

12 December 2020

1 reference

12 December 2020

Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer

1 reference

12 December 2020

Inflammation in Alzheimer disease: driving force, bystander or beneficial response?

1 reference

12 December 2020

Alzheimer's disease: epidemiology.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD2896

1 reference

22 August 2017

1 reference

PubMed ID

20431570